





CONTAINS CONFIDENTIAL PATIENT INFORMATION **New-to-Market Drugs** Prior Authorization of Benefits (PAB) Form Complete form in its entirety and fax to: Prior Authorization of Benefits Center at 1-844-512-9004 Provider Help Desk 1-800-454-3730

1. Patient information		2. Physician information			
Patient name:		Prescribing physician:			
Patient ID #·		Physician address:			
Patient ID #:		Physician phone #:			
Patient DOB:		Physician fax #:			
Date of Rx:		Physician specialty:			
		Physician DEA:			
Patient phone #:		Physician NPI #:			
Patient email address:		Physician email address:			
3. Medication	4. Strength	5. Directions	6. Quantity per 30 days		
			Specify:		

7. Diagnosis:

8. Approval criteria: CHECK ALL BOXES THAT APPLY

Note: Any areas not filled out are considered not applicable to your patient and MAY AFFECT THE OUTCOME of this request.

Prior authorization is required for new-to-market drugs not yet reviewed by the Iowa Medicaid Pharmaceutical & Therapeutics (P&T) Committee. Payment will be considered for patients when the following criteria are met:

- 1) Patient has an FDA approved or compendia indication for the requested drug; and
- 2) If the requested drug falls in a therapeutic category/class with existing prior authorization criteria, the requested drug must meet the criteria for the same indication; or
- 3) If no clinical criteria are established for the requested drug, patient has tried and failed at least two preferred drugs, when available, from the Iowa Medicaid Preferred Drug List (PDL) for the submitted indication; and
- 4) Request must adhere to all FDA approved labeling.

The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.

Once new-to-market drugs are reviewed by the P&T Committee, they will be placed on the PDL which will dictate ongoing PA criteria, if applicable.

Drug name:			Strength:			
Dosage instructions: Diagnosis:		Quantity:		Day's supply:		
Preferred	drug	trial	1:	Drug	name/dose:	
Trial start date:		Trial		end	date:	
Reason for failur	e:					







An Anthem Company

CONTAINS CONFIDENTIAL PATIENT INFORMATION New-to-Market Drugs Prior Authorization of Benefits (PAB) Form Complete form in its entirety and fax to:

Prior Authorization of Benefits Center at 1-844-512-9004

Patient name:								
Preferred	drug	trial	2:	Drug	name/dose:			
			Trial	start	date:			
			Trial end date:					
Reason for failu	re:							
Pertinent lab da	ta:							
Other medical c	onditions to cons	ider:						
Other relevant i	nformation:							
Possible drug interactions/conflicting drug therapies:								
Attach lab resul	its and other doci	umentation as i	necessary.					

Patient name:

Patient ID #:

9. Physician signature

Prescriber or authorized signature

Date

Prior Authorization of Benefits is not the practice of medicine or the substitute for the independent medical judgment of a treating physician. Only a treating physician can determine what medications are appropriate for a patient. Please refer to the applicable plan for the detailed information regarding benefits, conditions, limitations, and exclusions. The submitting provider certifies that the information provided is true, accurate, and complete and the requested services are medically indicated and necessary to the health of the patient.

Note: Payment is subject to member eligibility. Authorization does not guarantee payment.

The document(s) accompanying this transmission may contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation.

If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately and arrange for the return or destruction of these documents.

PAGE 2 OF 2